Volume 5.04 | Feb 4

Hematopoiesis News 5.04 February 4, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
 
TOP STORY
Split Decision: Stem Cell Signal Linked with Cancer Growth
Researchers identified a protein critical to hematopoietic stem cell function and blood formation. The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth. [Press release from University of California, San Diego School of Medicine discussing online prepublication in Nature Genetics] Press Release | Abstract
New Cord Banking Software Solution from STEMSOFT
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Erythropoietin Guides Multipotent Hematopoietic Progenitor Cells toward an Erythroid Fate
Investigators observed that high systemic levels of erythropoietin reprogram the transcriptomes of multi- and bipotent hematopoietic stem/progenitor cells in vivo. This induces erythroid lineage bias at all lineage bifurcations known to exist between hematopoietic stem cells (HSCs) and committed erythroid progenitors, leading to increased erythroid and decreased myeloid HSC output. [J Exp Med] Abstract

HSC Commitment-Associated Epigenetic Signature Is Prognostic in Acute Myeloid Leukemia
The authors delineated DNA cytosine methylation profiles of highly purified long-term hematopoietic stem cells (HSC), short-term HSC, common myeloid progenitors, and megakaryocyte-erythrocyte progenitors from the BM of healthy human individuals. They showed that an epigenetic stem cell commitment-specific signature is highly prognostic for overall survival of patients with acute myeloid leukemia. [J Clin Invest]
Full Article | Press Release

Attenuation of MicroRNA-126 Expression that Drives CD34+38- Stem/Progenitor Cells in Acute Myeloid Leukemia Leads to Tumor Eradication
To address the need for therapeutic targets in leukemic stem-like cells (LSC), researchers compared microRNA expression patterns in highly enriched healthy CD34+CD38- hematopoietic stem cells, CD34+CD38- LSC and CD34+CD38+ leukemic progenitors, all derived from the same patients’ bone marrow specimens. [Cancer Res] Abstract

In Vivo Evidence for an Instructive Role of Fms-Like Tyrosine Kinase-3 (FLT3) Ligand in Hematopoietic Development
In vivo administration of FLT3 ligand (FLT3L) promotes expansion of progenitors with combined myeloid and lymphoid potential. To investigate further the role of this cytokine in hematopoietic development, researchers generated transgenic mice expressing high levels of human FLT3L. [Haematologica] Abstract | Full Article

Hypercholesterolemia-Induced Priming of Hematopoietic Stem and Progenitor Cells Aggravates Atherosclerosis
Scientists investigated how hypercholesterolemia affects hematopoietic stem and progenitor cell (HSPC) biology and atherosclerosis. Hypercholesterolemia induced loss of HSPC quiescence, characterized by increased proliferation and expression of cyclin B1, C1, and D1, and a decreased expression of Rb, resulting in a 3.6- fold increase in the number of HSPCs in hypercholesterolemic Ldlr−/− mice. [FASEB J] Abstract

Frozen Cord Blood Hematopoietic Stem Cells Differentiate into Higher Numbers of Functional Natural Killer Cells In Vitro than Mobilized Hematopoietic Stem Cells or Freshly Isolated Cord Blood Hematopoietic Stem Cells
Investigators compared the capacity of frozen or freshly isolated umbilical cord blood hematopoietic stem cells and frozen mobilized peripheral blood hematopoietic stem cells to generate natural killer cells in vitro. [PLoS One] Full Article

Lethal Giant Larvae 1 Tumor Suppressor Activity Is Not Conserved in Models of Mammalian T and B Cell Leukemia
In lethal giant larvae-negative (Lgl1-/-) mice, the authors analyzed the development of hematopoietic malignancies either alone, or in the presence of common oncogenic lesions. They showed that in the absence of Lgl1, production of mature white blood cell lineages and long-term survival of mice are not affected. [PLoS One] Full Article

Gadd45a Deletion Aggravates Hematopoietic Stem Cell Dysfunction in ATM-Deficient Mice
Researchers report that Gadd45a deletion did not rescue the defects of T-cells and B-cells development in ataxia telangiectasia mutated-deficient (ATM-/-) mice. Instead, ATM and Gadd45a double knockout hematopoietic stem cells (HSCs) exhibited an aggravated defect in long-term self-renewal capacity compared to ATM-/- HSCs in HSC transplantation experiments. [Protein Cell] Full Article

CLINICAL RESEARCH

Phosphatidylinositol-3-Kinase Delta Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
In this single-group, open-label, Phase II study, 125 patients with indolent non-Hodgkin’s lymphomas who had not had a response to rituximab and an alkylating agent or had had a relapse within six months after receipt of those therapies were administered idelalisib, 150 mg twice daily, until the disease progressed or the patient withdrew from the study. [N Engl J Med] Abstract | Press Release

Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Hodgkin Lymphoma: A Report from the German Hodgkin Study Group
Researchers retrospectively analyzed incidence, outcome and risk factors for the development of therapy-related acute myeloid leukemia and myelodysplastic syndromes after Hodgkin lymphoma. [Blood] Abstract

Win a $25 Amazon Gift Card!
Connexon Creative is evaluating reader interest in a new social media platform. Fill out this quick survey for your chance to win 1 of 4 $25 gift cards! Take survey here


Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
 
REVIEWS
Bosutinib: A Review of Preclinical and Clinical Studies in Chronic Myelogenous Leukemia
Imatinib continues to represent the treatment of choice for chronic myeloid leukemia (CML). However, some patients develop resistance or intolerance to imatinib or to other second-generation tyrosine kinase inhibitors. Bosutinib shows a good therapeutic activity with a benign safety profile, no cardiovascular toxicity, and offers an important therapeutic addition to the armamentarium that physicians can use against resistant CML. [Exp Opin Pharmacother] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Strategies to Inhibit GvHD while Sparing the Graft-versus-Tumor Response: Finding the Sweet Spot
 
INDUSTRY NEWS
STEMSOFT Software Inc. and JAF Consulting, Inc. Announce Collaborative Partnership
STEMSOFT Software Inc. and JAF Consulting, Inc. announced their collaborative partnership. As a STEMSOFT Certified Consulting Partner, JAF will provide STEMSOFT clients the opportunity to engage in JAF’s expertise and individualized computer validation, regulatory compliance and quality systems management services. [STEMSOFT Software Inc.] Press Release

Stem Cell Agency Funds More than $66 Million in Research Including New Genomics Initiative
A team bringing together experts and investigators from seven different major California institutions has been awarded $40 million to create a new Center of Excellence in Stem Cell Genomics, by California’s stem cell agency, the California Institute for Regenerative Medicine. [California Institute for Regenerative Medicine]
Press Release

TotipotentRX and ThermoGenesis Achieve Bone Marrow Stem Cell Transplant Milestone
ThermoGenesis Corp. and TotipotentRX Corporation announced the TotipotentRX cellular therapy clinical team in partnership with Fortis Healthcare, Gurgaon (New Delhi) has achieved its 20th pediatric bone marrow transplant. [ThermoGenesis Corp.] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2014 Highlights of ASH® in Asia
March 29-30, 2014
Singapore, Singapore

Visit our events page to see a complete list of events in the hematopoiesis research community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Positions – New Models of Hematopoiesis and Hematopoietic Disorders (Mount Sinai Medical Center)

NEW Assistant Professorship – Hematopoietic Stem Cells and Microenvironment (University of Zurich)

NEW Lab Technologist – Human Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Hematopoietic Stem Cell and Leukemia Research (City of Hope)

Postdoctoral Position – Hematopoietic Stem Cell Physiology and Bone Marrow Failure (University of Michigan)

Research Associate – Normal & Leukemic Stem Cells (King’s College London)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Scientific Affairs Coordinator (American Society of Hematology)

Postdoctoral Position – Erythroid and Myeloid Differentiation of Hematopoietic Stem Cells (Imagine Institute)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us